



Stock Symbol:

NNVC

(NYSE American)

**NanoViricides at a Key Inflection Point in Valuation with
First Drug Ready for Phase II Clinical Trials**

Anil R. Diwan, PhD

President & Exec. Chairman

Mobile: +1 (203) 606-9180

email: adiwan@nanoviricides.com

Disclosure Statement

NanoViricides, Inc. is a NYSE-American listed publicly traded company (stock symbol: NNVC).

This is not an offering memorandum and should not be construed as such. It is provided as a non-confidential document for informational purposes only.

[NanoViricides, Inc](#) is a clinical stage company that is creating special purpose nanomaterials as therapeutics against a number of different viruses. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped and non-enveloped virus particles and to dismantle them. All of our drug candidates are based on broad and exclusive worldwide licenses in perpetuity from TheraCour Pharma, Inc. for the development of drugs to combat viral infections of Human Coronaviruses, Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Viruses (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu viruses, Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis virus, viruses causing viral Conjunctivitis (a disease of the eye). The Company's technology is based on broad, exclusive, sub-licensable, perpetual field licenses to all drugs developed in the licensed field areas (virus indications) from TheraCour Pharma, Inc. The Company obtains additional licenses after determining that it intends to pursue a drug candidate in the licensed field into commercialization. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, covering all drugs for the licensed field of application, as established at its foundation in 2005.

This document contains forward-looking statements that reflect the current expectation of NanoViricides, Inc. (the "Company") regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements are "forward-looking statements" within the meaning of Section 27A of the Securities 18 Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements.

The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.

Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

NanoViricides, Inc (NNVC) Company Overview...December 2024

- Vision: Develop Nanomachine Antiviral Drugs to Revolutionize Treatment of Antiviral Infections the way Penicillin Revolutionized Treatment of Bacterial Infections
 - Not a Vaccine, but a Treatment After Infection of the Patient
 - Broad-Spectrum antiviral drugs - one drug “cures” many viral diseases
 - Works even on variants...copy the receptor site which stays the same
- Lead Drug, NV-387 completed Phase I Clinical Trial Successfully
- Phase II-Ready for: RSV, Influenza incl. Bird Flu H5N1, COVID, MPOX/Smallpox
- Specific Drugs in Pipeline: NV-HHV-1 (VZV Shingles, HSV-1, HSV-2); NV-HIV-1 (HIV/AIDS); And Many More

Focus: Unmet Medical Needs...We Have Solutions Already!

- RSV : No Treatment. Major Concern for Newborns and Early Age.
- Influenza / Bird Flu : Viruses Mutate Rapidly Threatening Bird Flu Pandemic from a Drug-Resistant Virus
- MPox / Smallpox : Urgent Need with TPOXX Clinical Trial Failure
- COVID / Long COVID : Out-of-Mind is NOT Out-of-Sight!

- Herpes Viruses : Linked to Alzheimer's; Latent "Forever" Infections
- HIV/AIDS : Latent "Forever" Infection

Host-Mimetic NanoViricides' Platform... Superior to All Other Current Antiviral Technologies

MCM Technology Attribute	Vaccines	Antibodies	Small Chemicals	Nanoviricides
Resistance to Viral Escape Via Variants?	NO. Changing Virus Necessitates New Development	NO. Changing Virus Necessitates New Development	NO. Not Amenable to Rapid New development	YES. Drug Remains Active in Face of Changing Virus
Broad Antiviral Activity Spectrum?	NO. Very Narrow Spectrum; Specific to Few Strains	NO. Very Narrow Spectrum; Specific to Few Strains	Limited by Natural Development of Resistant Variants	YES. "Tunable" from One to Multiple Virus Families
Flexibility in Routes of Administration (RoA's)?	NO. Mostly Injections, Some Oral, Nasal likely	NO. Infusions Required	Some Oral, Some Infusions	YES. Oral, Inhalation, Injection, Infusion, Nasal Spray, Cream/Ointment
Safe, Well Tolerated with No Side Reactions?	NO. Given to Large, Healthy Population	NO. Limitations Exist.	Limited Safety and Tolerability	YES. No Reportable AEs in Phase I
Can Treat All Subjects?	NO. Limitations Exist.	NO. Limitations Exist.	NO. Limitations from DDI, Inherent Toxicities, etc.	YES. Enabled by Strong Safety and Multiple RoA's

Viruses Highly Unlikely to Escape a NanoViricide Drug - by Design!

Example: NV-387, A Single Drug Effective Against Family of Viruses; ...NV-387 Superior to Existing Drugs*

Virus Family	Virus; Animal Model	% Improvement in Survival, Compared to Reference Drug
RSV	RSV, A2 Balb-c Mice Lethal Lung Infection	NV-387, PO, Led to Full Survival, Possibly Cured Lethal Viral Infection Vs. Ribavirin Increased Survival by only ~ 7 Days
Influenza	Influenza A /California/2/2014 (H3N2) Balb-c Mice Lethal Lung Infection	NV-387, PO = 350% Vs. Xofluza® Baloxavir, PO = 150% Rapivab® Peramivir, IV = 150%, Compared to Tamiflu® Oseltamivir, PO, Taken As 100%
Coronaviruses	hCoV-NL-63 (SARS-CoV-2 Surrogate) Rats Lethal Lung Infection	NV-387, IV = 450% NV-387, PO = 170%, Compared to Veklury® Remdesivir, IV, Taken As 100%
Orthopox Viruses (Smallpox/MPox)	Ectromelia (orthopoxvirus) SCID-Balb-c Mice Lethal Lung Infection	NV-387, PO = 175% NV-387-m-T*, PO = 225% Compared to TPOXX® Tecovirimat, PO, Taken As 100%
* In Lethal Animal Infection Models		NV-387-m-T: Tecovirimat Mixed into NV-387; demonstrates improved effect, when taken together (orthogonal mechanisms).

**NV-387 Mimics Host-Side Sulfated Glycoprotein Features Used by
Over 90% of Human Pathogenic Viruses!**

WIN-WIN For NanoViricides Investor and Inventor: Large Market Sizes

Virus Family	Nanoviricide Drug Candidate	Market Size, Global Estimated		
		2025 \$ Billions	CAGR	2030 \$ Billions
RSV	NV-387	3,1	18 %	7,0
Influenza; H5N1 Bird Flu	NV-387	5,0	8,35 %	7,5
Coronaviruses	NV-387	2,0	?	2,7
Orthopox Viruses (Smallpox / MPox)	NV-387	0,5	?	0,5
Shingles	NV-HHV-1	1	?	~2
HSV-1 “Cold Sores”, HSV-2 “Genital Ulcers”	NV-HHV-1, NV-HHV-2	2,9	8,1 %	4,3
HIV/AIDS	NV-HIV-1	9,4	6,4 %	12,8
Dengue, Chikengunya, Ebola/Marburg, Others, Emerging and Novel Viruses	NV-387, Others	2	6,4 %	2,7
Overall		25,9		37,5

**NV-387 Alone Plays in a Market Size of Over \$17 Billion (2030)!
Single Drug, Multiple Indications = High ROI**

NanoViricides is a Unique Drug Developer Company with Its Own cGMP-Capable Manufacturing Capability

- Discovery to Drug Product Capabilities In-House
 - Nanomedicines Characterization Facility
 - Virology BSL-2 Certified Lab
 - Protect Proprietary Technology & Intellectual Property
- Highly Customizable and Flexible Clinical Drug Product Pharma Manufacturing Capability
 - Rapid Transfer from Lab Bench to cGMP Manufacture
 - Significant Time and Cost Savings
 - Skin Creams, Eye Drops, Gels, Injectables, Oral...
- Manufacture Commercial Drug Products for Market Entry & Early Revenues



NanoViricides - Robust Drug Pipeline !

		Drug Substance	Indication	Lead Id.	Animal Efficacy Efficacy	IND-Enabling Studies	Phase I	Phase II	Phase III
1	Attack Re-Infection Cycle	NV-387	RSV						
2			COVID						
3			MPox/Smallpox						
4			Influenza						
5		NV-HHV-1 (Skin Cream)	Shingles (VZV)						
6			Cold Sores (HSV-1)						
7			Genital Ulcers (HSV-2)						
8		NV-HIV-1	HIV/AIDS						
9*	Cures	NV-387-g-X	Curing DNA Viruses						Attack Both the “Re-Infection Cycle” and the “Replication Cycle” Parts for Complete LifeCycle Inhibition And Thus Cure of Most Viruses
10*		NV-387-g-Y	Curing RNA Viruses						
>		Several Additional R&D Programs in Progress							
* #9 and #10 are Advanced Development Programs to Develop “Cures” for Most DNA and RNA Viral Infections, rsp.				X and Y are Proprietary, Patentable Chemicals Designed to Block the Replication Part of the Lifecycle of the Virus, While NV-387 Itself Is Designed to Block the Re-Infection Part of the Virus Lifecycle. Thus the Drugs NV-387-g-X and NV-387-g-Y Would Block the Complete Virus Lifecycle of DNA and RNA Viruses Respectively. “g” Refers to Encapsulation of the Guest (X or Y) Within the NV-387 Nanomicelles.					

Strong, Multi-Talented Executive Team

Anil R. Diwan, PhD President & Exec. Chairman

Co-Founder

Led Uplisting to NYSE-American Exchange in 2013
Raised Over \$100M

Co-Inventor of Nanoviricides™ & of TheraCour®
25+ years Leadership & Entrepreneurial experience
Key Patents, Several NIH SBIR Awards
PhD (Biochem Eng - Rice), BTech (ChemEng - IITB)
Ranked 9th All India on JEE to IITs (1975)

Krishna Menon, VMD, MRCS, PhD Consulting Pre-Clinical Studies

30+ Years of Pharmaceutical Industry Experience in Drug
Discovery and Pre-clinical Regulatory Development
Eli Lilly President's Award

AZT, GemCitabine, Pemetrexed (Alimta) Development

Eli-Lilly, Dana-Farber, Beth-Israel, Bayer Alumnus

Meeta R. Vyas, MBA CFO

30+ years Experience in Corporate Performance Improvement,
Finance, M&A, EBITDA Growth...

Previously: Principal, The Gores Group; Director, Kamyon
Capital; CEO, Signature Brands, Inc. (a public company, known
for "Mr. Coffee"); Ran \$1B GE Appliances Division; Consultant,
McKinsey & Company

MBA (Finance) Columbia U, BS (ChemEng) MIT

Jayant Tatake, PhD VP, R&D

30+ Years of Pharmaceutical Industry Experience in Drug
Discovery, Manufacturing, QA/QC, CRO, Synthesis, Scale-up,
Formulations, and Pharmaceutical cGMP Expertise

Former Asst. Director, Pharma. Analytics,
InterPharm, Inc.

Co-Inventor of Nanoviricides® & TheraCour®
PhD, UICT, Mumbai, India

Multi-skilled, Experienced Board of Directors

Anil R. Diwan, PhD
President & Exec. Chairman

Co-Founder, Led Uplisting to NYSE-Amer. in 2013, Raised \$100M+, Co-Inventor of Nanoviricides™ & of TheraCour®
30+ years Leadership & Entrepreneurial experience

(Not an Independent Board Member)
Director and Chairman Since Founding in 2005

Mak Jawadekar, PhD ✓

35+ Years of Pharmaceutical Industry Experience, Pharma Strategic Consultant. Previously at Pfizer, Inc., as Director, Portfolio Management & Analytics, and as Vice President, Asia Colleague Resource Group, in Pfizer Global R&D. Business and Research experience in joint ventures, alliance management, contracting, pharma R&D, drug delivery, clinical supply manufacture, etc. Global experience working with United States, Europe, India, Japan, China.

Independent Board Member since February, 2020

Hon'ble Theodore "Todd" Rokita, JD ✓

Presently Attorney General, State of Indiana. Former US Rep. from Indiana (4 terms since 2010). Served on several House Committees. Co-owner, Apex Benefits Group, Inc. Extensive executive, team-building, business strategy, and fiscal management expertise in the private sector, alongside his public service leadership experience. Serves or has served as a Member of the Board of Directors of several commercial and charitable institutions.


Independent Board Member since May, 2020

Brian M. Zucker, CPA ✓

30+ years of experience as a CPA specializing in the securities industry. A Partner at CFO Financial Partners, LLC (<https://www.cfopartners.com/>). Also serves as the CFO and Financial Operations Principal for numerous broker dealers and hedge funds. Partner at RRBB Accountants & Advisors. CFO of EIG Energy Partners Capital Markets, LLC. Ex-Senior Consultant at Deloitte Haskins & Sells and at Price Waterhouse. Mr. Zucker holds several FINRA licenses.

Independent Board Member since November, 2020

✓ = Independent Board Member



NanoViricides
Incorporated

“Bind-Engulf-Destroy” Viruses
A Publicly Traded Company, “NNVC”

www.nanoviricides.com

**NanoViricides Attack Re-infection & Replication Cycles...
Complete Lifecycle Inhibition of Most Viruses & Their Variants!**

